Literature DB >> 20447545

Aldosterone/renin ratio determines peripheral and central blood pressure values over a broad range.

Andreas Tomaschitz1, Winfried Maerz, Stefan Pilz, Eberhard Ritz, Hubert Scharnagl, Wilfried Renner, Bernhard O Boehm, Astrid Fahrleitner-Pammer, Gisela Weihrauch, Harald Dobnig.   

Abstract

OBJECTIVES: With the present analysis we intended to investigate the magnitude of the effect of relative aldosterone excess in predicting peripheral as well as aortic blood pressure levels in a well-characterized cohort of patients undergoing coronary angiography.
BACKGROUND: The discussion on the relationship between aldosterone concentration and blood pressure has recently gone beyond the role of primary aldosteronism in the genesis of arterial hypertension.
METHODS: Plasma aldosterone (pg/ml) and plasma renin concentration (pg/ml) were determined in 3,056 Caucasian patients (age 62.5 +/- 11 years; 31.9% women) scheduled for coronary angiography in a single tertiary care center. We formed sex-specific deciles (D) according to plasma aldosterone/renin concentration ratio (ARR) (pg/ml/pg/ml).
RESULTS: Mean peripheral systolic blood pressure (SBP) and diastolic blood pressure (DBP) of the entire cohort were 141 +/- 24 mm Hg and 81 +/- 11 mm Hg, respectively. Mean ARR was 10.2 +/- 15.7 in men and 14.4 +/- 19.9 in women (p < 0.0001). Median SBP and aortic SBP increased steadily and significantly from ARR D1 (126.8 mm Hg and 130.0 mm Hg, respectively) to D10 (151.0 mm Hg and 149.6 mm Hg, respectively; p < 0.0001 for both) after multivariate adjustment for age, sex, body mass index, renal function, antihypertensive medications, and various parameters potentially influencing BP. Adjusted median DBP and aortic DBP also increased significantly from 74.3 mm Hg and 66.5 mm Hg (D1) to 86.9 mm Hg and 76.7 mm Hg, respectively (D10) (p < 0.001 for both). In a multivariate stepwise regression model, ARR emerged as the second most significant independent predictor (after age) of mean SBP and as the most important predictor of mean DBP in this patient cohort.
CONCLUSIONS: Our results: 1) underline that the ARR affects BP well below a cutoff used for screening for primary aldosteronism; and 2) illustrate the importance of the ARR in modulating BP over a much wider range than is currently appreciated. Copyright 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20447545     DOI: 10.1016/j.jacc.2010.01.032

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  14 in total

1.  Aldosterone predicts major adverse cardiovascular events in patients with acute myocardial infarction.

Authors:  Matthew Fomonyuy Yuyun; Sandeep K Jutla; Paulene A Quinn; Leong L Ng
Journal:  Heart Asia       Date:  2012-08-24

2.  TASK-3 channel deletion in mice recapitulates low-renin essential hypertension.

Authors:  Nick A Guagliardo; Junlan Yao; Changlong Hu; Elaine M Schertz; David A Tyson; Robert M Carey; Douglas A Bayliss; Paula Q Barrett
Journal:  Hypertension       Date:  2012-04-09       Impact factor: 10.190

3.  Dysregulated aldosterone secretion in persons of African descent with endothelin-1 gene variants.

Authors:  Jia W Tan; Tina Gupta; Worapaka Manosroi; Tham M Yao; Paul N Hopkins; Jonathan S Williams; Gail K Adler; Jose R Romero; Gordon H Williams
Journal:  JCI Insight       Date:  2017-12-07

4.  Chronic renin inhibition lowers blood pressure and reduces upright muscle sympathetic nerve activity in hypertensive seniors.

Authors:  Yoshiyuki Okada; Sara S Jarvis; Stuart A Best; Tiffany B Bivens; Beverley Adams-Huet; Benjamin D Levine; Qi Fu
Journal:  J Physiol       Date:  2013-09-23       Impact factor: 5.182

5.  Dietary Sodium Modifies Serum Uric Acid Concentrations in Humans.

Authors:  Alwyn S Todd; Robert J Walker; Robert J MacGinley; Jaimon Kelly; Tony R Merriman; Tanya J Major; Richard J Johnson
Journal:  Am J Hypertens       Date:  2017-11-06       Impact factor: 2.689

6.  Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial.

Authors:  Andreas Tomaschitz; Astrid Fahrleitner-Pammer; Burkert Pieske; Nicolas Verheyen; Karin Amrein; Eberhard Ritz; Katharina Kienreich; Jörg H Horina; Albrecht Schmidt; Elisabeth Kraigher-Krainer; Caterina Colantonio; Andreas Meinitzer; Stefan Pilz
Journal:  BMC Endocr Disord       Date:  2012-09-13       Impact factor: 2.763

7.  Primary Aldosteronism With Type 2 Diabetes Mellitus Requires More Antihypertensive Drugs for Blood Pressure Control: A Retrospective Observational Study.

Authors:  Kennosuke Ohashi; Takeshi Hayashi; Yui Watanabe; Koichiro Hara; Rikako Ukichi; Hiroshi Asano; Hirofumi Suzuki; Kenji Yamashiro; Katsuyoshi Tojo; Masaya Sakamoto; Kazunori Utsunomiya
Journal:  J Clin Med Res       Date:  2017-12-01

8.  Aldosterone to active renin ratio is associated with nocturnal blood pressure in obese and treated hypertensive patients: the Styrian Hypertension Study.

Authors:  Martin R Grübler; Katharina Kienreich; Martin Gaksch; Nicolas Verheyen; Astrid Fahrleitner-Pammer; Johannes Schmid; Jana Grogorenz; Klemens Ablasser; Burkert Pieske; Andreas Tomaschitz; Stefan Pilz
Journal:  J Clin Hypertens (Greenwich)       Date:  2014-03-26       Impact factor: 3.738

9.  Associations of central and peripheral blood pressure with the renin-angiotensin-aldosterone system in healthy young adults: the African-PREDICT study.

Authors:  Lebo F Gafane-Matemane; Nametsegang L Mokae; Yolandi Breet; Marko Poglitsch; Aletta E Schutte
Journal:  Hypertens Res       Date:  2020-10-30       Impact factor: 3.872

10.  Long-Term Consumption of Cuban Policosanol Lowers Central and Brachial Blood Pressure and Improves Lipid Profile With Enhancement of Lipoprotein Properties in Healthy Korean Participants.

Authors:  Suk-Jeong Kim; Dhananjay Yadav; Hye-Jeong Park; Jae-Ryong Kim; Kyung-Hyun Cho
Journal:  Front Physiol       Date:  2018-04-24       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.